Journal
DIABETES OBESITY & METABOLISM
Volume 15, Issue 3, Pages 264-271Publisher
WILEY
DOI: 10.1111/dom.12026
Keywords
cardiovascular disease; exenatide; GLP-1; glycaemic control; type 2 diabetes
Categories
Funding
- Amylin Pharmaceuticals, LLC
- Eli Lilly Company
- Novo Nordisk
- Sanofi
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Takeda
- Merck
Ask authors/readers for more resources
Aims Type 2 diabetes mellitus (T2DM) is often associated with cardiovascular (CV) risk factors such as obesity, hypertension and dyslipidemia. The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1 receptor agonist, on glycaemic control and CV risk factors. Methods This analysis included 675 Intent-to-Treat patients with T2DM [baseline (mean +/- SD) HbA1c, 8.1 +/- 1.2%; fasting blood glucose (FBG), 166 +/- 48?mg/dl; weight, 94.3 +/- 19.4?kg; systolic/diastolic blood pressure (SBP/DBP), 129 +/- 15/78 +/- 9 mm?Hg; total cholesterol, 178.5 +/- 41.9?mg/dl; low-density lipoprotein (LDL), 100.1 +/- 35.0?mg/dl; high-density lipoprotein (HDL), 44.5 +/- 11.6?mg/dl; triglycerides, 155.6 +/- 3.3?mg/dl; alanine aminotransferase (ALT), 32.1 +/- 19.5 U/l] treated with diet and exercise alone or in combination with metformin, sulfonylurea, and/or thiazolidinedione who received 52?weeks of ExQW in four clinical trials. Results At 52?weeks, ExQW significantly improved HbA1c [mean (SE) change from baseline, -1.3 (0.05)%], FBG [-36.3 (2.02) mg/dl], body weight [-2.6 (0.19) kg], SBP/DBP [-3.6 (0.56) mm?Hg/-1.2 (0.34) mm?Hg], total cholesterol, -4.4 (1.33) mg/dl; LDL, -2.6 (1.08) mg/dl; HDL, 1.1 (0.31) mg/dl; triglycerides, -7 (1.6)%], and ALT [-4.3 (0.71) IU/l] concentrations, with greater improvements in patients with elevated analyte levels at baseline. Improvements were observed across a range of background antihyperglycaemia therapies. Of patients completing 52?weeks, 19% achieved the composite American Diabetes Association goal (HbA1c < 7.0%, BP < 130/80 mm?Hg, LDL?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available